Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;46(2):357-365.
doi: 10.1016/j.rdc.2020.01.014.

The Future of Axial Spondyloathritis Treatment

Sinead Maguire  1 , Raj Sengupta  2 , Finbar O'Shea  3
Affiliations
Review

The Future of Axial Spondyloathritis Treatment

Sinead Maguire et al. Rheum Dis Clin North Am. 2020 May.

Abstract

Axial spondyloathritis (axSpA) treatment with biologic DMARDs was previously focused around anti-TNF agents. Significant advances in research have led to new therapeutic options, such as secukinumab, an IL-17 inhibitor, which has been approved for the treatment of axSpA. Two other biologic agents that are already licensed for rheumatoid and psoriatic arthritis, tofacitinib and ixekizumab, have demonstrated improved outcomes in axSpA. Several newer agents have been developed to inhibit IL-17, IL-23, and JAK. Early trials are promising; however, further research is needed. Rapid expansion of therapies available to treat axSpA could lead to improved disease control and decreased disease burden.

Keywords: Ankylosing spondylitis; Axial spondyloarthritis; Spondyloarthritis; Therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have nothing to disclose.

MeSH terms